Duopharma Biotech Bhd Asset Resilience Ratio
Duopharma Biotech Bhd asset resilience ratio. Duopharma Biotech Bhd (7148) has an Asset Resilience Ratio of 20.08% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Duopharma Biotech Bhd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Duopharma Biotech Bhd (2016–2024)
Asset resilience ratio of Duopharma Biotech Bhd from 2016 to 2024. This chart shows how Duopharma Biotech Bhd's Asset Resilience Ratio has changed over time. Read Duopharma Biotech Bhd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Duopharma Biotech Bhd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 7148 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | RM290.87 Million | 20.08% |
| Short-term Investments | RM0.00 | 0% |
| Total Liquid Assets | RM290.87 Million | 20.08% |
Asset Resilience Insights
- Good Liquidity Position: Duopharma Biotech Bhd maintains a healthy 20.08% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Duopharma Biotech Bhd Industry Peers by Asset Resilience Ratio
Compare Duopharma Biotech Bhd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Duopharma Biotech Bhd Asset Resilience Ratio by Year (2016–2024)
Duopharma Biotech Bhd asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Duopharma Biotech Bhd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 11.71% | RM161.25 Million ≈ $40.48 Million |
RM1.38 Billion ≈ $345.72 Million |
-12.35pp |
| 2023-12-31 | 24.06% | RM323.59 Million ≈ $81.24 Million |
RM1.35 Billion ≈ $337.72 Million |
+17.71pp |
| 2022-12-31 | 6.34% | RM77.49 Million ≈ $19.46 Million |
RM1.22 Billion ≈ $306.78 Million |
+3.73pp |
| 2021-12-31 | 2.62% | RM30.45 Million ≈ $7.64 Million |
RM1.16 Billion ≈ $292.27 Million |
-2.37pp |
| 2020-12-31 | 4.99% | RM52.81 Million ≈ $13.26 Million |
RM1.06 Billion ≈ $265.74 Million |
+0.46pp |
| 2019-12-31 | 4.53% | RM41.67 Million ≈ $10.46 Million |
RM919.80 Million ≈ $230.93 Million |
+1.94pp |
| 2018-12-31 | 2.59% | RM21.70 Million ≈ $5.45 Million |
RM836.38 Million ≈ $209.99 Million |
-4.33pp |
| 2017-12-31 | 6.93% | RM48.86 Million ≈ $12.27 Million |
RM705.24 Million ≈ $177.06 Million |
-5.84pp |
| 2016-12-31 | 12.77% | RM84.48 Million ≈ $21.21 Million |
RM661.46 Million ≈ $166.07 Million |
-- |
About Duopharma Biotech Bhd
Duopharma Biotech Berhad, together with its subsidiaries, researches, develops, manufactures, markets, sells, imports, and distributes pharmaceutical products and medicines in Malaysia and internationally. It offers consumer healthcare products, including vitamins, minerals, and supplements under the Flavettes, PROVITON, PROVITON STR, CHAMPS, and Naturalle brand names; analgesics and antitussives… Read more